TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05614492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual PrEP Decision Aid
Description: Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC PrEP Video
Description: A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared PrEP Decision Aid
Description: Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
Study: NCT05808686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ischemic Conditioning
Description: We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
Study: NCT06376526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg
Study: NCT05332600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drop-jump test
Description: The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
Study: NCT05193214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-PD-1 humanized monoclonal antibody injection
Description: Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
Study: NCT05094622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
Study: NCT05497180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive myofunctional appliance
Description: passive myofunctional appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard oral appliance
Description: standard oral appliance
Study: NCT05098028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Rifaximin ER
Description: Low Dose Rifaximin Extended Release Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Rifaximin DER
Description: Low Dose Rifaximin Delayed Extended Release Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Rifaximin ER
Description: High Dose Rifaximin Extended Release Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Rifaximin DER
Description: High Dose Rifaximin Delayed Extended Release Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Twice Daily
Study: NCT05752760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum 299v Freeze Dried Capsule
Description: The intervention is a probiotic lactobacillus that is contained in food products in the US

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Freeze Dried Potato Starch Capsule
Description: The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
Study: NCT04463771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
Study: NCT06459739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacral ESPB
Description: sacral ESPB
Study: NCT04463771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat will be administered orally BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat will be administered orally BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: pemigatinib will be administered orally QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN2385 will be administered every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN2390 will be administered every 2 weeks
Study: NCT06404099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil Placebo
Description: The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solriamfetol
Description: The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solriamfetol Placebo
Description: The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Study: NCT06366737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KILBON Appliance
Description: palatal TAD assissted lingual appliance for en-mass retraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAT appliance
Description: palatal TAD assissted clear aligner
Study: NCT06479590

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application
Study: NCT05457790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT Intervention
Description: 1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: 1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
Study: NCT05979064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopically harvested omental tissue autograft
Description: 1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity.
Study: NCT06212804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIS954
Description: A humanized IgG4 monoclonal antibody.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: VIS954 Placebo
Study: NCT05842031

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: Identify what interventions may be helpful in improving quality of life.

Intervention type: BEHAVIORAL
Intervention: Patient Educational Needs
Description: Identify what interventions may be helpful in improving patient educational needs

Intervention type: BEHAVIORAL
Intervention: Symptom Management
Description: Identify what interventions may be helpful in improving symptom management Improve symptom management
Study: NCT05952349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)
Description: 44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin (1000 mg Twice a day)
Description: 44 Patients with PCOS receiving Metformin 1000mg (BD)
Study: NCT05957679

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRE and routine MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment and Recording
Description: Undergo grading and recording of tumor stiffness and adhesion during surgery
Study: NCT05382494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate 50mcg Nasal Spray
Description: Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9 % Nasal Spray
Description: Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
Study: NCT06241742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Single, oral dose of HT-6184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Single, oral dose of placebo
Study: NCT04935957

Intervention type: DEVICE
Group type: OTHER
Intervention: GLUCUBE device
Description: device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
Study: NCT06444412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga 68 PSMA-11
Description: Contrast dye given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05470673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole
Description: Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft alone
Description: Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
Study: NCT05803031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melaleuca Alternifolia Oil
Description: Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal debridement
Description: Scaling and root surface debridement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal debridement
Description: Scaling and root surface debridement
Study: NCT05763810

Intervention type: OTHER
Group type: OTHER
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block

Intervention type: OTHER
Group type: OTHER
Intervention: Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
Description: Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
Study: NCT03655132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Acceptance and Commitment Therapy for Chronic Pain
Description: Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
Study: NCT06583941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Virtiva Plus
Description: Participants will consume a low dose of Virtiva Plus (120mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (120mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Virtiva Plus
Description: Participants will consume a high dose of Virtiva Plus (240mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (240mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
Study: NCT05216250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BOTOX
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BOTOX
Description: Intramuscular injection
Study: NCT04819464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg.
Study: NCT06360458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Description: Intravenous injection of methylprednisolone sodium succinate (Chongqing Lai Mei Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomisation. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Methylprednisolone sodium succinate simulant)
Description: Intravenous injection of placebo (methylprednisolone sodium succinate simulant) (Chongqing Lai Mei Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomisation. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
Study: NCT05007613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: Cabozantinib (Cabometyx) 40 MG PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection
Description: atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
Study: NCT05514600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of parastomal hernia fascial defect
Description: For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.